4 ms·

Yeah, feel free to spend the $1200/mo for it then. Because that's off-label use when there are drugs in this class with on-label weight loss use. And sometime t

by bedast 4y ago

Yeah, feel free to spend the $1200/mo for it then. Because that's off-label use when there are drugs in this class with on-label weight loss use. And sometime this year, tirzepatide is expected to be among them. The coupon was changed because people were abusing it. This drug is approved for diabetes, not weight loss.

__Parfait__ 4y ago
Don't worry, it will be approved for the latter soon enough, perhaps under a different brand. No way to put this genie back in the bottle, sorry.
- bedast 4y ago
  Yes, this is what Novo Nordisk did with Victoza around 2014 with the release of Saxenda. And then again with Ozempic around 2021 with Wegovy. These weight loss versions exist. And there will be one likely this year based on tirzepatide from Lilly (I haven't looked up if they have a name for it yet).
  - finneganscat 4y ago
    [dead]
counttheforks 4y ago
Why are you defending the price gouging of the american healthcare system? Do you really only care about yourself?
- bedast 4y ago
  I care that many people I know are losing glycemic control because they're going on a waiting list for their medication while Kim K and Elon Musk and TikTok promote easy mode cosmetic weight loss.
  - serf 4y ago
    if someone is 'losing glycemic control' because they can't get a specific new en-vogue med, then their doctor is doing a poor job. there is a very big problem with blaming the suffering who find relief with this drug -- regardless of what their ailment is -- rather than blaming the systems and processes that lead to a supposed shortage that urged a price adjustment. forgive me for diving into conspiracy for a second here.. do you really think for a second that the pharmaceutical groups responsible for this class of drug do not have the facilities to ramp up production? They absolutely do -- the problem here is that since it's a gold-mine there is even more cash capture to occur with an added scarcity element, hence the price adjustment. The price adjustment wasn't to champion the diabetics over the obese, it was to make more MONEY.
    - bedast 4y ago
      You are among the people just learning about this class of drug. It's been around since 2004 (Byetta). I've been taking it since 2012 (Victoza). Even then, it was known to promote weight loss (Saxenda approved around 2014). This is not a new hotness. And many diabetics have used this drug class for a long time. And yeah, you're jumping into conspiracy theory. Ramping up production would likely take significant investment. Do they have the resources? Probably. But given the weight loss benefit is temporary (seriously, it is, ask anyone who has used one of these drugs for a significant amount of time), do you think they're going to sink significant investment into production when demand is going to wane in a few years? Well, you see, their investors are going to say no, and they hold the final say.
  - BeFlatXIII 4y ago
    Seems like the problem is that not enough is produced to meet real demand instead of mere regulator-approved demand.

by bedast 4y ago

__Parfait__ 4y ago

Don't worry, it will be approved for the latter soon enough, perhaps under a different brand. No way to put this genie back in the bottle, sorry.

bedast 4y ago
Yes, this is what Novo Nordisk did with Victoza around 2014 with the release of Saxenda. And then again with Ozempic around 2021 with Wegovy. These weight loss versions exist. And there will be one likely this year based on tirzepatide from Lilly (I haven't looked up if they have a name for it yet).
- finneganscat 4y ago
  [dead]

counttheforks 4y ago

Why are you defending the price gouging of the american healthcare system? Do you really only care about yourself?

bedast 4y ago
I care that many people I know are losing glycemic control because they're going on a waiting list for their medication while Kim K and Elon Musk and TikTok promote easy mode cosmetic weight loss.
- serf 4y ago
  if someone is 'losing glycemic control' because they can't get a specific new en-vogue med, then their doctor is doing a poor job. there is a very big problem with blaming the suffering who find relief with this drug -- regardless of what their ailment is -- rather than blaming the systems and processes that lead to a supposed shortage that urged a price adjustment. forgive me for diving into conspiracy for a second here.. do you really think for a second that the pharmaceutical groups responsible for this class of drug do not have the facilities to ramp up production? They absolutely do -- the problem here is that since it's a gold-mine there is even more cash capture to occur with an added scarcity element, hence the price adjustment. The price adjustment wasn't to champion the diabetics over the obese, it was to make more MONEY.
  - bedast 4y ago
    You are among the people just learning about this class of drug. It's been around since 2004 (Byetta). I've been taking it since 2012 (Victoza). Even then, it was known to promote weight loss (Saxenda approved around 2014). This is not a new hotness. And many diabetics have used this drug class for a long time. And yeah, you're jumping into conspiracy theory. Ramping up production would likely take significant investment. Do they have the resources? Probably. But given the weight loss benefit is temporary (seriously, it is, ask anyone who has used one of these drugs for a significant amount of time), do you think they're going to sink significant investment into production when demand is going to wane in a few years? Well, you see, their investors are going to say no, and they hold the final say.
- BeFlatXIII 4y ago
  Seems like the problem is that not enough is produced to meet real demand instead of mere regulator-approved demand.